At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 203 enrolled
Drug / intervention
Placebo +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 28-Day Study Evaluating the Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet (SCH 39641) in Adult Subjects 50 Years of Age and Older With Ragweed-Induced Rhinoconjunctivitis (Protocol No. P06081)
In Brief
A Phase 2 clinical trial evaluating Placebo and SCH 39641 for Rhinoconjunctivitis and 3 related conditions. Completed, enrolled 203 participants.
Detailed Summary
The purpose of this study was to assess the safety and tolerability of a ragweed allergy immunotherapy tablet (AIT) administered sublingually (under-the tongue) in subjects 50 years of age and older with ragweed-induced rhinoconjunctivitis, with or without asthma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRhinoconjunctivitis, Rhinitis, Conjunctivitis, Allergy
Countries--
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedSep 2009
Enrollment StartNov 2009
Primary CompletionFeb 2010
TodayJul 2026
First PostedSep 16, 2009
Enrollment StartNov 1, 2009
Primary CompletionFeb 1, 2010
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 16.8 years ago
Interventions
Placebodrug
Placebo sublingual tablet, once daily
SCH 39641biological
Allergy immunotherapy tablet (sublingual)
SCH 39641biological
Allergy immunotherapy tablet (sublingual)